Connect with us

Private Equity

8 VC-Backed Startups Helping Treat COVID-19

As the COVID-19 pandemic continues to impact the world, many U.S. VC-backed startups are helping fight the virus by developing, testing, and implementing treatments that can manage, alleviate, or even prevent the symptoms of COVID-19.  The venture industry is proud to support these innovative companies by providing capital and strategic guidance that is essential to […]

The post 8 VC-Backed Startups Helping Treat COVID-19 appeared first on National Venture Capital Association – NVCA.

Avatar

Published

on

As the COVID-19 pandemic continues to impact the world, many U.S. VC-backed startups are helping fight the virus by developing, testing, and implementing treatments that can manage, alleviate, or even prevent the symptoms of COVID-19.  The venture industry is proud to support these innovative companies by providing capital and strategic guidance that is essential to tackling the crisis.

These healthcare companies have shifted their resources to specifically address COVID-19 by developing new treatments for patients infected with the virus, or adapting treatments they had already created to help COVID-19 patients.

NVCA has created a Startups Combating COVID tracker with many examples of startups supporting the fight against COVID-19. Here are a few highlights of those companies that are working on treatments for COVID-19:

1. Adaptive Biotechnologies

Adaptive Biotechnologies and Amgen have partnered to combine expertise to discover and develop a neutralizing antibody targeting the COVID-19 virus to potentially speed the recovery from, or even prevent, COVID-19. Neutralizing antibodies defend healthy cells by interfering with the function of an invading virus. These antibodies may be used to treat someone currently fighting the disease and provide passive immunity to people who have recently been exposed to the virus.

2. Applied Therapeutics

Applied Therapeutics’s clinical stage treatment ‘AT-001’ is being utilized in several hospitals in New York City to address acute lung inflammation and cardiomyopathy in critical COVID-19 patients. AT-001 is currently being accessed in these New York City hospitals via “Named Patient” Emergency INDs or Investigator-Initiated Trials, depending on the patient circumstance and hospital institution.

3. Celularity Inc.

Celularity Inc. is expanding its collaboration with United Therapeutics to use Celularity’s proprietary cell-therapy ‘CYNK-001’ for the treatment of COVID-19. This cell-therapy could reduce the amount of virus found in patients with COVID-19. Celularity’s drug is a “natural killer” cell therapy that could attack cells infected with the COVID-19 virus.

4. Cytovia Therapeutics

Cytovia Therapeutics is developing an antibody designed to activate virus-killing cells in the body to block the virus from entering cells, preventing COVID-19 from spreading in patients. Natural Killer cells are a first line of defense against severe acute infectious diseases. Cytovia’s treatment has the potential to minimize the virus escaping from immune responses, inhibiting the intensification of respiratory inflammation, and potentially destroying virus-infected cells while also blocking the entry of the virus into cells.

5. Humanigen Inc.

Humanigen Inc. is conducting clinical trials with its drug Lenzilumab, which may reduce serious or fatal outcomes in COVID-19 patients. These clinical trials have so far shown that in high-risk COVID-19 patients with severe pneumonia, Lenzilumab was associated with improved clinical outcomes.

6. Partner Therapeutics

Partner Therapeutics has initiated clinical trials of its drug Leukine in patients with acute respiratory failure associated with COVID-19. The trials will evaluate the effect of Leukine on improving lung function in COVID-19 patients and helping them recover more quickly, so fewer will need to go into intensive care. Leukine could also aid the production of antibodies against the virus and help restore lung cells damaged by COVID-19.

7. SAB Biotherapeutics

SAB Biotherapeutics is working to develop an antibody therapeutic candidate for COVID-19 that may be used both as a treatment for patients already infected with the virus, and for immediate protection (passive immunity) when a vaccine is not an option. This new therapy could have significant value for use to protect front-line responders, mission-critical staff, and high-risk populations, such as the elderly and immune compromised.

8. Sarepta Therapeutics

Sarepta Therapeutics is working with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to utilize Sarepta’s proprietary RNA platform as possible treatments for COVID-19. Previously published clinical and preclinical studies of Sarepta’s RNA technology have found evidence of antiviral activity of Sarepta’s technology in coronaviruses and other viruses.

Learn more about the critical work being done by VC-backed companies to combat COVID-19 on our tracker on our COVID-19 webpage.

And if you are a VC that has a portfolio company that is working on COVID-19 related issues, or are a VC-backed company working on COVID-19 issues, please share your story with us by completing this short survey.

Source: https://nvca.org/8-vc-backed-startups-helping-treat-covid-19/

Private Equity

20VC: Sequoia’s Roelof Botha on His Biggest Lessons Working Alongside Don Valentine, Mike Moritz and Doug Leone, Leading Sequoia’s US Business and What Sequoia Do To Retain Their Edge at the Top & The Crucible Moments That Define Startup Success

Roleof Botha is a Partner @ Sequoia Capital, one of the world’s leading venture firms with a portfolio including the likes of Airbnb, Instacart, Stripe, UiPath, Zoom, the list goes on. As for Roelof, at Sequoia he has led rounds into the likes of YouTube, Instagram, Eventbrite, Square, MongoDB, 23andMe and Unity Technologies to name a few. Before joining the

The post 20VC: Sequoia’s Roelof Botha on His Biggest Lessons Working Alongside Don Valentine, Mike Moritz and Doug Leone, Leading Sequoia’s US Business and What Sequoia Do To Retain Their Edge at the Top & The Crucible Moments That Define Startup Success appeared first on The Twenty Minute VC.

Avatar

Published

on

Roleof Botha is a Partner @ Sequoia Capital, one of the world’s leading venture firms with a portfolio including the likes of Airbnb, Instacart, Stripe, UiPath, Zoom, the list goes on. As for Roelof, at Sequoia he has led rounds into the likes of YouTube, Instagram, Eventbrite, Square, MongoDB, 23andMe and Unity Technologies to name a few. Before joining the world of venture, Roelof was the CFO @ Paypal playing a key role in their hyper-growth from 2000-2003.

CLICK TO LISTEN ON ITUNES

In Today’s Episode You Will Learn:

1.) How did Roelof go from actuary in South Africa to CFO @ Paypal? What were his biggest lessons from seeing Paypal burn $10M per month? How did Paypal lead to his joining Sequoia as a Partner?

2.) Market Evaluation: Does Roelof agree that the market is crazy today? How does today compare to prior vintages? How does Roelof assess the compression of fundraising timelines? With compressed timelines, how does he build relationships of trust with founders?

3.) Founder Evaluation: What were Roelof’s lessons on founder assessment from Don Valentine? What matrix did Don teach Roelof to assess founders on? How does Roelof feel about the rise of competitive rounds? When should founders take them vs remain heads down on execution?

4.) Investment Mentality: How did Roelof prevent becoming too confident when early investments went well? How does Roelof prevent relying on past failures as a reason for turning down opportunities today? What can investors do to retain a very flexible mind? Why does Roelof believe you are only as good as your next investment?

5.) Sequoia’s Edge: How does Roloef think about what it takes for Sequoia to retain it’s edge at the top? How does Roloef measure the success of the Sequoia scout program? How did they structure it? How has the structure changed? What do they plan to do moving forward?

6.) Board Membership: How would Roloef evaluate his current style of board membership? How has that style changed over time? What elements did he find challenging? What advice would Roelof give to new board members adopting their first board seats?

Items Mentioned In Today’s Show:

Roelof’s Favourite Book: Man’s Search For Meaning

Roelof’s Most Recent Investment: mmhmm

As always you can follow Harry and The Twenty Minute VC on Twitter here!

Likewise, you can follow Harry on Instagram here for mojito madness and all things 20VC.

Source: https://thetwentyminutevc.com/roelofbotha/

Continue Reading

Private Equity

Private equity investor Centerbridge Partners backs Syncapay’s acquisition of Wirecard North America

From: FinTech Global Syncapay has announced that it has bought Wirecard North America, marking another page in the story of the collapse of the scandal-ridden former FinTech giant. Wirecard imploded this summer after a suspected multi-billion dollar fraud was unearthed. Since then the company, which was once hailed as one of Germany’s biggest FinTech success […]

Avatar

Published

on

From: FinTech Global
Syncapay has announced that it has bought Wirecard North America, marking another page in the story

Source: https://www.altassets.net/private-equity-news/by-news-type/deal-news/private-equity-investor-centerbridge-partners-backs-syncapays-acquisition-of-wirecard-north-america.html

Continue Reading

Private Equity

Gulf Capital backs CWB as part of $60mln IP platform build

To read this article, you must be a paid subscription member. (Current members login here) […]

The post Gulf Capital backs CWB as part of mln IP platform build first appeared on https://africacapitaldigest.com.

Avatar

Published

on



To read this article, you must be a paid subscription member. (Current members login here)

Reserve your digital subscription today

Join now for $35 per month

Join now for $395 per year

for access to:

  • Weekly newsletter with original and curated news, analysis and perspective
  • Africa’s private capital deals, fund raises and the investment firms and executives involved
  • Portfolio company news that impacts value and stakeholder participation
  • Job moves and partnerships between leading market participants
  • Exclusive access to Africa Capital Digest’s full content archive

If you’d like more information on exceptional value group subscriptions for your colleagues and teams, please contact Teresa Hall at thall[at]africacapitaldigest.com today.

Source: https://africacapitaldigest.com/gulf-capital-backs-cwb-as-part-of-60mln-ip-platform-build/

Continue Reading
Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Press Releases2 hours ago

Hospital Outsourcing Market Size Worth $679.2 Billion By 2027: Grand View Research, Inc.

Press Releases2 hours ago

Villarreal Law Firm, a Leading Team of Trucking Accident Attorneys in Brownsville, Announces Archive on Trucking Accident Issues

Press Releases2 hours ago

Remodeling Market is Projected to Expand at 3.9% CAGR Through 2026; Global Market Insights, Inc.

Press Releases2 hours ago

TerraPay refuerza su entrada en Norteamérica con la licencia MSB en FINTRAC de Canadá

Press Releases2 hours ago

GVG appelle les décideurs à se saisir du potentiel du Big data

Press Releases2 hours ago

Remodeling Market is Projected to Expand at 3.9% CAGR Through 2026; Global Market Insights, Inc.

Press Releases2 hours ago

TerraPay consolide son arrivée en Amérique du Nord en obtenant la licence d’entreprise de services monétaires du CANAFE au Canada

Private Equity2 hours ago

20VC: Sequoia’s Roelof Botha on His Biggest Lessons Working Alongside Don Valentine, Mike Moritz and Doug Leone, Leading Sequoia’s US Business and What Sequoia Do To Retain Their Edge at the Top & The Crucible Moments That Define Startup Success

Private Equity3 hours ago

Private equity investor Centerbridge Partners backs Syncapay’s acquisition of Wirecard North America

Startup3 hours ago

The Unheard Story of Xero Degrees and Their Adorable Outlet at Patiala

Press Releases4 hours ago

DAS „AMERICAN HORROR STORY”-MÖRDERHAUS ÖFFNET ZUM ERSTEN MAL FÜR PARANORMALE HALLOWEEN-WOCHENEND-LIVESTREAM FÜR DIE ÖFFENTLICHKEIT

Press Releases4 hours ago

Biophytis Enrolls First Patient in Brazil in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure

Press Releases4 hours ago

Court of Arbitration for Sport (CAS) Invalidates World Athletics Rule Imposing Burden of Proof on Disabled Athletes to Prove No Competitive Advantage as Unlawful and Discriminatory, But Then Bars Double-Amputee Sprinter Blake Leeper from Competing on His Blades on Racially Discriminatory Grounds

Venture Capital5 hours ago

Australian Cyber Week 2020 showcases vibrant, growing sector

Startup5 hours ago

How to get job at Google? Things you should know while applying for a job at Google

Press Releases5 hours ago

De Havilland Canada Livre Deux Avions Dash 8-400 à Ethiopian Airlines

Saas5 hours ago

Saas5 hours ago

Saas5 hours ago

Saas5 hours ago

Saas5 hours ago

Saas5 hours ago

Saas5 hours ago

Saas5 hours ago

Saas5 hours ago

Saas5 hours ago

Press Releases5 hours ago

Canntab to Launch in Australia and Participate in Australia’s Largest Cannabis Research Study

Press Releases6 hours ago

TES Invests In Green Li-ion’s Cutting Edge Battery Recycling Technology

Press Releases6 hours ago

New Data On Mayne Pharma’s Tolsura® (SUBA®-itraconazole) Presented At IDWeek 2020

Startup6 hours ago

Tesla recalls nearly 50,000 Model S and X cars exported to China due to safety concerns over faulty suspensions

Trending